Lobar pentamidine levels and Pneumocystis carinii pneumonia following aerosolized pentamidine.
Recent studies have suggested that failure of pentamidine prophylaxis against Pneumocystis carinii pneumonia (PCP) may be due to reduced deposition of pentamidine in the upper lobes. In this study, we performed bronchoalveolar lavage from the apical segment of the upper lobe and the middle lobe in 51 HIV-positive patients, all of whom were receiving prophylaxis with aerosolized pentamidine, who had presented with acute respiratory symptoms. Lavage fluid from each lobe was assayed for pentamidine using high-performance liquid chromatography (HPLC). The number of clusters of P carinii were counted after staining with a Wright-Giemsa stain. The patients were subclassified as PCP-positive (32 patients) and PCP-negative (19 patients) on the basis of the presence/absence of P carinii clusters in their BAL fluid. The concentration of pentamidine in the upper lobe compared with the middle lobe was no different (using paired Student's t tests) for either PCP-positive patients or PCP-negative patients. In comparing the positive with the negative subjects, using unpaired Student's t test, there was no difference in the concentration of pentamidine in the upper lobe or the middle lobe. For PCP-positive patients, the numbers of P carinii clusters were on average higher in the upper lobes (mean +/- SD: upper = 14.9 +/- 16.6, middle 7.5 +/- 10.8, p = 0.013, paired Student's t test), but there was no correlation between lobar P carinii cluster counts and pentamidine levels. We conclude that the absence of a relationship between cluster count and pentamidine level, the similarity in regional pentamidine levels between upper and middle lobes, as well as the similarity in pentamidine levels between the PCP-positive and PCP-negative groups indicate that the regional dose of pentamidine is not the determining factor as to whether aerosolized pentamidine prophylaxis will succeed or fail.
O'Riordan
T G
TG
Department of Medicine, State University of New York at Stony Brook.
Baughman
R P
RP
Dohn
M N
MN
Smaldone
G C
GC
D000328:Adult; D000336:Aerosols; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry* / Q000166:cytology / Q000382:microbiology; D002851:Chromatography, High Pressure Liquid; D015169:Colony Count, Microbial; D005500:Follow-Up Studies; D006679:HIV Seropositivity; D006801:Humans; D008168:Lung / Q000737:chemistry* / Q000382:microbiology / Q000473:pathology; D009330:Nebulizers and Vaporizers; D010419:Pentamidine / Q000008:administration & dosage / Q000032:analysis* / Q000627:therapeutic use*; D011010:Pneumocystis / Q000302:isolation & purification; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy / Q000517:prevention & control*; D013997:Time Factors
D000336:Aerosols; D010419:Pentamidine